Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Panel Supports Class II Status For Oxygenation Circuit Devices, And Two Other Categories

This article was originally published in The Gray Sheet

Executive Summary

The Circulatory System Devices Panel supported class II, with special controls, reclassification proposals from FDA for extracorporeal membrane oxygenators; external cardiac compressors; and external pacemaker pulse generators and triple chamber pacing system analyzers. But the panel had some additional requests for further action by the agency.

You may also be interested in...

Oxygenation Circuit Devices Find A Class II Home With FDA

The agency issued a final order reclassifying and renaming membrane lung devices to acknowledge their role as one component of a larger extracorporeal membrane oxygenation (ECMO) system. The decision follows 2013 and 2014 advisory panel recommendations.

FDA Proposes Class II Status For External Pacemaker Pulse Generators, Analyzers

External pacemaker pulse generators and pacing system analyzers would move from class III to class II with special controls in a Sept. 15 proposed order. For most of the products, the 510(k) route would be maintained, but triple-chamber PSAs would move from PMA to 510(k) review under the proposal. .

FDA Panel Supports Down-Classification For ECMO Circuits

After much debate, FDA’s Circulatory System Devices panel formed a consensus in support of a class II, special controls designation for extracorporeal circuits for long-term pulmonary and cardiopulmonary support in adults.

Related Content


Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts